



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/068,171

02/04/2002

Sally Mossman

210121.721

8073

500 7590 05/28/2008

SEED INTELLECTUAL PROPERTY LAW GROUP PLLC  
701 FIFTH AVE  
SUITE 5400  
SEATTLE, WA 98104

EXAMINER

WANG, SHENGJUN

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

05/28/2008

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/068,171	<b>Applicant(s)</b> MOSSMAN ET AL.	
	<b>Examiner</b> Shengjun Wang	<b>Art Unit</b> 1617	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 11 February 2008.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 91,94,96-100,105-113 and 117-128 is/are pending in the application.
- 4a) Of the above claim(s) 96-98,100,108-110,112,113,120 and 122-126 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 91,94,99, 105-107,111,117-119,121,127,128 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

Receipt of applicants' amendments and remarks, and the 132 declaration submitted February 11, 2008 is acknowledged.

#### ***Claim Rejections 35 U.S.C. 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Claims 91, 94, 99, 105, 111, 117, 121, 127-128 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (US 6,113,918, IDS) in view of Kensil et al. (US 5,057,540), and in further view of applicants' own admission.

3. Johnson et al. teach that aminoalkyl glucosamine phosphates, including the particular elected AGP herein, are known as adjuvant, and immunoeffectors. Johnson further teaches that the adjuvants composition may be in various forms including oil-in-water or water-in-oil emulsions, aqueous composition, liposome, etc; vaccine composition comprising the AGP and antigen. Johnson et al. also teach a method of using the AGP for enhancing the immune response of an animal. See, particularly, the abstract, columns 2-5, example 20 in column 42, and the claims.

4. Johnson et al do not teach expressly the employment of a combination of AGP and Quil A for enhancing the immune response.

5. However, Kensil et al. teaches that Quil A, and its' fractions including QS 21, is known to be useful as immune adjuvant, which is useful for stimulating immune response, particularly

Art Unit: 1617

co-administered with antigen. The adjuvant may be administered individually or admixed with a variety of other adjuvants to achieve the enhancements of the immune response to antigen, including those of tuberculosis. See, particularly, the abstract, column 6, line 54 to column 7, lines 40, and the claims.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed the invention was made, to make a composition comprising the two adjuvants herein, i.e., Quil A and the particular AGP herein, and optionally further comprising antigen, such as those for tuberculosis.

A person of ordinary skill in the art would have been motivated to composition comprising the two adjuvants herein, i.e., Quil A and the particular AGP herein, and optionally further comprising antigen, such as those for tuberculosis because it is prima facie obvious to combine two compositions each of which is taught in the prior art to be useful for same purpose in order to form third composition that is to be used for very the same purpose; idea of combining them flows logically from their having been individually taught in prior art; thus , the claimed invention which is a combination of two known adjuvants sets forth prima facie obvious subject matter. See In re Kerkhoven, 205 USPQ 1069. Further, the prior arts teach the concomitant application of Quil A with other adjuvants. As to the particularly amount of each active ingredients herein, note, the optimization of a result effective parameter, e.g., amounts of the active ingredients in a pharmaceutical composition, is considered within the skill of the artisan. See, In re Boesch and Slaney (CCPA) 204 USPQ 215. With respect to the particular antigen herein, note applicants acknowledged that such antigen was known in the art. See the example 1 herein at page 74. Using a known antigen properly is within the skill of artisan. As to

Art Unit: 1617

the recitation “enhancing CTL immune response”, in the preamble of the claims, it is noted that this recitation gives little “life and meaning” to the claims as it does not limit any steps involved in the claimed method, or the subject being treated.

6. Claims 106, 107, 118, and 119 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (US 6,113,918, IDS) in view of Kensil et al. (US 5,057,540), and in further view of applicants’ own admission as set forth above, and in further view of De Vries et al.

7. Johnson et al. and Kensil et al. as a whole do not teach expressly the employment of phospholipid in the immunogenic composition employed herein.

8. However, De Vries et al. disclosed that for immunogenic composition with antigens, surfactants, such as phospholipids, are known to be useful, particularly with saponin. See, particularly, the abstract, col. 3, lines 9-62, and the claims.

9.

Therefore, it would have been prima facie obvious to a person of ordinary skill in the art, at the time the claimed invention was made, to incorporate surfactants, such as phospholipids in the aqueous immunogenic composition.

A person of ordinary skill in the art would have been motivated to incorporate surfactants, such as phospholipids in the aqueous immunogenic composition because surfactants, such as phospholipids, are known to be useful in such composition for stabilizing the antigen containing composition.

10. Claims 91, 94-95, 99, 102, 105, 111, 114, 117, 121, 127 and 128 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (US 6,113,918, IDS) in view of Kensil et al. (US 5,057,540), and in further view of applicants’ own admission, for reasons discussed

Art Unit: 1617

above, and in further view of Johnson (US 2001/0053363, IDS) or Mossman et al. (WO 02/03961, IDS).

11. Johnson and Mossman et al. provide further motivation to combine the two adjuvants, AGP and Quil A. Particularly, Mossman et al. teach that AGP and Quil A are useful together and disclose a composition comprising both AGP and Quil A, See, particularly, claims 32 and 42. The AGP disclosed by Mossman including those herein employed see the figures. Johnson also discloses that saponin and AGP adjuvants are useful together and may produce synergistic effect. See, particularly example 7 at pages 28-29. Therefore, one of ordinary skill in the art, would have been further motivated to combine the two adjuvants as herein claimed, since it have been shown that two adjuvants are useful together as have been expected, and may produce synergistic effect.

12. Claims 106, 107, 118, and 119 are rejected under 35 U.S.C. 103(a) as being unpatentable over Johnson et al. (US 6,113,918, IDS) in view of Kensil et al. (US 5,057,540), and in further view of applicants' own admission as set forth above, and in further view of De Vrier et al, for reasons set forth above, and in further view of Johnson (US 2001/0053363, IDS) or Mossman et al. (WO 02/03961, IDS).

13. Johnson and Mossman et al. provide further motivation to combine the two adjuvants, AGP and Quil A. Particularly, Mossman et al. teach that AGP and Quil A are useful together and disclose a composition comprising both AGP and Quil A, See, particularly, claims 32 and 42. The AGP disclosed by Mossman including those herein employed see the figures. Johnson also discloses that saponin and AGP adjuvants are useful together and may produce synergistic effect. See, particularly example 7 at pages 28-29. Therefore, one of ordinary skill in the art, would

Art Unit: 1617

have been further motivated to combine the two adjuvants as herein claimed, since it have been shown that two adjuvants are useful together, and may produce synergistic effect.

***Response to the Arguments***

Applicants' amendments and remarks, and the 132 declaration submitted February 11, 2008 have been fully considered, but are not persuasive for reasons discussed below.

14. The declaration under 37 CFR 1.132 filed February 11, 2008 is insufficient to overcome the rejection of claims 91, 94, 99, 105, 111, 117, 121, 127 and 128 based upon Johnson et al. (US 6,113,918, IDS) in view of Kensil et al. (US 5,057,540), and in further view of applicants' own admission as set forth in the last Office action because: the declaration fails to establish a unexpected result commensurate in scope with claimed invention that is sufficient to rebut the prima facie case of obviousness on the record. Particularly, the declaration is persuasive to establish that QS-7 is similarly useful as QS-21, but fails to establish that the alleged synergistic effect are unexpected and significant compared to the prior art.

15. The examiner maintains that a prima facie case of unexpected results residing in claimed invention has not been established. As discussed in the prior office action, for establishment of unexpected results, a few notable principles are well settled. It is applicant's burden to explain any proffered data and establish how any results therein should be taken to be unexpected and significant. See MPEP 716.02 (b). The claims must be commensurate in the scope with any evidence of unexpected results. See MPEP 716.02 (d). Further, A DECLARATION UNDER 37 CFR 1.132 must compare the claimed subject matter with the closest prior art in order to be effective to rebut a prima facie case of obviousness. See, MPEP 716.02 (e). Applicants assert a synergistic effect of claimed combination in the aspect of enhancing CTL immune response. In

Art Unit: 1617

the examiner's view, the evidences on the record fails to establish a prima facie case of unexpected and significant benefit residing in the claimed invention. *The claims must be commensurate in the scope with any evidence of unexpected results.*

Applicants contend that

“it is not Applicants' burden to prove that all other possible combinations of adjuvants are not synergistic in order to establish that the claimed combinations are non-obvious. Applicants have demonstrated synergistic effects for multiple combinations within the scope of the current claims. Further, as there is no general expectation in the field of immunology that synergistic effects will be achieved when two given adjuvants are combined, Applicants' demonstration of synergy in the context of the claimed invention must be properly viewed as an unexpected result.”

The examiner respectfully disagrees. The prior art teach that AGP and Quil A are useful together and disclose a composition comprising both AGP and Quil A, the prior art also discloses that saponin and AGP adjuvants are useful together and may produce synergistic effect. One of ordinary skill in the art would have reasonable expected that combination of two different adjuvants, such as AGP and a saponin would be better than a sing adjuvants.

16. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.



Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Shengjun Wang/  
Primary Examiner, Art Unit 1617